Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Tom Drolet who wrote (1685)	4/21/1999 6:56:00 AM
From: Mark Bartlett	Read Replies (2) \| Respond to of 14101

Tom, <<That said , the piece on CTV at 6pm and the internet articles where unfair to Celebrex in that the % are low-- and there is no direct cause and effect attribution.>> There certainly is some truth to the above - but on the other hand, was Celebrex really tested for a long enough period to fairly assess its affect on the GI system? If memory serves me right (and I may be wrong here) they only reviewed the drug for those types of side-effects for a 12-24 week period - IMO hardly long enough when one considers most people take these drugs for much longer. I think we talked about this at the time the study info was released about 3-4 months ago when there was so much fanfare in the paper. Want a real eye-opener ... go to: celebrex.com; ....... especially the side effects area - does not look that impressive when one reads the data .... diclofenac taken orally looks to be just about as good as Celebrex. Hmmm - I wonder at 150th the concentration of diclofenac in the system (Pennsaid), who would win !!!! MB